Inotrem S.A.: Strategic Analysis of Precision Immunotherapy and European Health Autonomy
Strategic audit of Inotrem’s TREM-1 immunotherapy platform. Evaluating TRL 7 medical countermeasures for European biothreat preparedness and health sovereignty.
Inotrem S.A. is a Paris- and Nancy-based clinical-stage biotech company specializing in immunomodulatory therapies for acute inflammatory diseases. Its proprietary platform targets the TREM-1 immune receptor – a key amplifier of inflammation – aiming to restore balanced immune responses in life-threatening conditions[1]. The company’s flagship drug, nan…